Tralitin Combi Tablet 2.5/850mg
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
MFDS item code 201904183 · Approved 2019.06.14
This product's status changed to Expired on 2024.06.14. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to assist patients with type 2 diabetes in controlling their blood glucose levels by using a combination of linagliptin and metformin. When administered along with dietary and exercise therapies, it effectively aids in blood glucose management and helps to maintain stable blood sugar levels for patients. This can reduce the risk of complications associated with diabetes. Consistent usage is important for safe and effective treatment. This medication improves blood glucose control.
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should contain linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's previous metformin dose (e.g., patients taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their previous doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with Caution in the Following Patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with Caution in the Following Patients). Patients with renal impairment In patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate [eGFR] 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, this medicine may be used with the following dose adjustments. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do Not Administer to the Following Patients).
This medication contains two ingredients, metformin and linagliptin, which help control blood sugar levels. However, it can cause serious side effects like lactic acidosis, so it should not be used in patients with poor kidney function, liver issues, acute cardiac problems, or heart failure. Additionally, pregnant or breastfeeding women should not take this medication. Due to the risk of hypoglycemia, blood glucose should be carefully monitored when taken alongside insulin or sulfonylurea medications. This medication is sensitive to kidney function, and caution is particularly necessary in elderly individuals with reduced kidney function or in patients taking other drugs that may impact kidney performance. There may also be rare side effects like acute pancreatitis or blistering dermatitis, so if unusual symptoms occur, one should consult a doctor immediately. Moreover, due to the metformin component, vitamin B12 levels may decrease, so regular blood tests to monitor vitamin status are recommended. Alcohol consumption should be avoided during treatment, particularly since acute alcohol intoxication increases the risk of lactic acidosis. If iodine contrast agents used in radiological examinations are administered, this medication should be discontinued for a certain period before and after the test, and use should be resumed only after re-evaluating kidney function. This medication has not been adequately studied for safety and efficacy in children or adolescents, therefore it is not recommended for use in these age groups. In case of overdose, serious lactic acidosis can occur, so strict adherence to the prescribed dosage is necessary, and one should visit a medical institution if any unusual symptoms arise. Finally, this medication should be stored in a place away from moisture and out of reach of children, and it is advisable not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, it is best kept at room temperature between 1 and 30 degrees Celsius. This will help maintain the effectiveness of the medication over time.
Bright orange, double-convex, oval film-coated tablets
60 tablets (10 tablets/PTP X 6)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.